{
    "references": [
        {
            "bibentry": "Burns, A, Iliffe, S. Alzheimer's disease. BMJ 2009; 338: b158. PMID: 19196745",
            "process_entry": "True",
            "doi": "10.1136/bmj.b158",
            "pmid": "19196745",
            "xmlid": "CIT0001"
        },
        {
            "bibentry": "Francis, PT, Palmer, AM, Snape, M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137–47. PMID: 10071091",
            "process_entry": "True",
            "doi": "10.1136/jnnp.66.2.137",
            "pmid": "10071091",
            "pmcid": "PMC1736202",
            "xmlid": "CIT0002"
        },
        {
            "bibentry": "Singh, M, Kaur, M, Kukreja, H, et al. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 2013; 70: 165–88. PMID: 24148993",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2013.09.050",
            "pmid": "24148993",
            "xmlid": "CIT0003"
        },
        {
            "bibentry": "Furukawa-Hibi, Y, Alkam, T, Nitta, A, et al. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. Behav Brain Res 2011; 225: 222–9. PMID: 21820013",
            "process_entry": "True",
            "doi": "10.1016/j.bbr.2011.07.035",
            "pmid": "21820013",
            "pmcid": "PMC4979006",
            "xmlid": "CIT0004"
        },
        {
            "bibentry": "Riederer, P, Lachenmayer, L, Laux, G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004; 11: 2033–43. PMID: 15279566",
            "process_entry": "True",
            "doi": "10.2174/0929867043364775",
            "pmid": "15279566",
            "xmlid": "CIT0005"
        },
        {
            "bibentry": "Knez, D, Sova, M, Košak, U, et al. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease. Future Med Chem 2017; 9: 811–32. PMID: 28504893",
            "process_entry": "True",
            "doi": "10.4155/fmc-2017-0036",
            "pmid": "28504893",
            "xmlid": "CIT0006"
        },
        {
            "bibentry": "Maria, JM, Pérez-Cruz, F, Saleta, VR, et al. Remarkable antioxidant properties of a series of hydroxy-3-arylcoumarins. Bioorg Med Chem 2013; 21: 3900–6. PMID: 23673214",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2013.04.015",
            "pmid": "23673214",
            "xmlid": "CIT0007"
        },
        {
            "bibentry": "Pu, WC, Lin, Y, Zhang, JS, et al. 3-Arylcoumarins: synthesis and potent anti-inflammatory activity. Bioorg Med Chem Lett 2014; 24: 5432–4. PMID: 25453803",
            "process_entry": "True",
            "doi": "10.1016/j.bmcl.2014.10.033",
            "pmid": "25453803",
            "xmlid": "CIT0008"
        },
        {
            "bibentry": "Zhao, HP, Yan, B, Peterson, LB, et al. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. ACS Med Chem Lett 2012; 3: 327–31. PMID: 23316269",
            "process_entry": "True",
            "doi": "10.1021/ml300018e",
            "pmid": "23316269",
            "pmcid": "PMC3539803",
            "xmlid": "CIT0009"
        },
        {
            "bibentry": "Nichols, DB, Leão, RAC, Basu, A, et al. Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors. Chem Biol Drug Des 2013; 81: 607–14. PMID: 23311976",
            "process_entry": "True",
            "doi": "10.1111/cbdd.12105",
            "pmid": "23311976",
            "xmlid": "CIT0010"
        },
        {
            "bibentry": "ElSeedi, HR. Antimicrobial Arylcoumarins from Asphodelus microcarpus. J Nat Prod 2007; 70: 118–20. PMID: 17253862",
            "process_entry": "True",
            "doi": "10.1021/np060444u",
            "pmid": "17253862",
            "xmlid": "CIT0011"
        },
        {
            "bibentry": "Wang, B, Li, N, Liu, T, et al. Synthesis and biological evaluation of novel neoflavonoid derivatives as potential antidiabetic agents. RSC Adv 2017; 7: 34448–60.",
            "process_entry": "True",
            "xmlid": "CIT0012"
        },
        {
            "bibentry": "Orhan, IE, Gulcan, HO. Coumarins: auspicious cholinesterase and monoamine oxidase inhibitors. Curr Top Med Chem 2015; 15: 1673–82. PMID: 25915613",
            "process_entry": "True",
            "doi": "10.2174/1568026615666150427113103",
            "pmid": "25915613",
            "xmlid": "CIT0013"
        },
        {
            "bibentry": "Secci, D, Carradori, S, Bolasco, A, et al. Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives. Eur J Med Chem 2011; 46: 4846–52. PMID: 21872365",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2011.07.017",
            "pmid": "21872365",
            "xmlid": "CIT0014"
        },
        {
            "bibentry": "Wang, ZM, Li, XM, Xue, GM, et al. Synthesis and evaluation of 6-substituted 3-arylcoumarin derivatives as multifunctional acetylcholinesterase/monoamine oxidase B dual inhibitors for the treatment of Alzheimer’s disease. RSC Adv 2015; 5: 104122–37.",
            "process_entry": "True",
            "xmlid": "CIT0015"
        },
        {
            "bibentry": "Anand, P, Singh, B, Singh, N. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease. Bioorg Med Chem 2012; 20: 1175–80. PMID: 22257528",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2011.12.042",
            "pmid": "22257528",
            "xmlid": "CIT0016"
        },
        {
            "bibentry": "Pisani, L, Farina, R, Catto, M, et al. Exploring basic tail modifications of coumarin-based dual acetylcholinesterase-monoamine oxidase B inhibitors: identification of water-soluble, brain-permeant neuroprotective multitarget agents. J Med Chem 2016; 59: 6791–806. PMID: 27347731",
            "process_entry": "True",
            "doi": "10.1021/acs.jmedchem.6b00562",
            "pmid": "27347731",
            "xmlid": "CIT0017"
        },
        {
            "bibentry": "Najafi, Z, Mahdavi, M, Saeedi, M, et al. Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer’s compounds: in vitro and in vivo biological evaluation and docking study. Bioorg Chem 2019; 83: 303–16.",
            "process_entry": "True",
            "xmlid": "CIT0018"
        },
        {
            "bibentry": "Yang, HL, Cai, P, Liu, QH, et al. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease. Eur J Med Chem 2017; 138: 715–28. PMID: 28728104",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2017.07.008",
            "pmid": "28728104",
            "xmlid": "CIT0019"
        },
        {
            "bibentry": "Pisani, L, Farina, R, Soto-Otero, R, et al. Searching for multi-targeting neurotherapeutics against Alzheimer’s: discovery of potent AChE-MAO B inhibitors through the decoration of the 2H-Chromen-2-one structural motif. Molecules 2016; 21: 362. PMID: 26999091",
            "process_entry": "True",
            "doi": "10.3390/molecules21030362",
            "pmid": "26999091",
            "pmcid": "PMC6273473",
            "xmlid": "CIT0020"
        },
        {
            "bibentry": "Patil, PO, Bari, SB, Firke, SD, et al. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease. Bioorg Med Chem 2013; 21: 2434–50. PMID: 23517722",
            "process_entry": "True",
            "doi": "10.1016/j.bmc.2013.02.017",
            "pmid": "23517722",
            "xmlid": "CIT0021"
        },
        {
            "bibentry": "Matos, MJ, Janeiro, P, González Franco, RM, et al. Synthesis, pharmacological study and docking calculations of new benzo[f] coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases. Future Med Chem 2014; 6: 371–83. PMID: 24635520",
            "process_entry": "True",
            "doi": "10.4155/fmc.14.9",
            "pmid": "24635520",
            "xmlid": "CIT0022"
        },
        {
            "bibentry": "Brühlmann, C, Ooms, F, Carrupt, PA, et al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem 2001; 44: 3195–8. PMID: 11543689",
            "process_entry": "True",
            "doi": "10.1021/jm010894d",
            "pmid": "11543689",
            "xmlid": "CIT0023"
        },
        {
            "bibentry": "Alipour, M, Khoobi, M, Nadri, H, et al. Synthesis of some new 3-coumaranone and coumarin derivatives as dual inhibitors of acetyl-and butyrylcholinesterase. Arch Pharm 2013; 44: 577–87.",
            "process_entry": "True",
            "xmlid": "CIT0024"
        },
        {
            "bibentry": "Ellman, GL, Courtney, KD, Andres, V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–95. PMID: 13726518",
            "process_entry": "True",
            "doi": "10.1016/0006-2952(61)90145-9",
            "pmid": "13726518",
            "xmlid": "CIT0025"
        },
        {
            "bibentry": "Holt, A, Sharman, DF, Baker, GB, et al. A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem 1997; 244: 384–92. PMID: 9025956",
            "process_entry": "True",
            "doi": "10.1006/abio.1996.9911",
            "pmid": "9025956",
            "xmlid": "CIT0026"
        },
        {
            "bibentry": "Youdim, MBH, Gross, A, Finberg, JPM. Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500–6. PMID: 11159700",
            "process_entry": "True",
            "doi": "10.1038/sj.bjp.0703826",
            "pmid": "11159700",
            "pmcid": "PMC1572573",
            "xmlid": "CIT0027"
        },
        {
            "bibentry": "Stafford, GI, Pedersen, PD, Jäger, AK, et al. Monoamine oxidase inhibition by southern African traditional medicinal plants. S Afr J. Bot 2007; 73: 384–90.",
            "process_entry": "True",
            "xmlid": "CIT0028"
        },
        {
            "bibentry": "Benzie, IFF, Strain, JJ. The Ferric Reducing Ability of Plasma (FRAP) as a measure of ‘‘Antioxidant Power’’: the FRAP assay. Anal Biochem 1996; 239: 70–6. PMID: 8660627",
            "process_entry": "True",
            "doi": "10.1006/abio.1996.0292",
            "pmid": "8660627",
            "xmlid": "CIT0029"
        },
        {
            "bibentry": "Hu, YH, Wang, B, Yang, J, et al. Synthesis and biological evaluation of 3-arylcoumarin derivatives as potential antidiabetic agents. J Enzyme Inhib Med Chem 2019; 34: 15–30. PMID: 30362362",
            "process_entry": "True",
            "doi": "10.1080/14756366.2018.1518958",
            "pmid": "30362362",
            "pmcid": "PMC6211316",
            "xmlid": "CIT0030"
        },
        {
            "bibentry": "Asadipour, A, Alipour, M, Jafari, M, et al. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem 2013; 70: 623–30. PMID: 24211638",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2013.10.024",
            "pmid": "24211638",
            "xmlid": "CIT0031"
        },
        {
            "bibentry": "Joubert, J, Foka, GB, Repsold, BP, et al. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem 2017; 125: 853–64. PMID: 27744252",
            "process_entry": "True",
            "doi": "10.1016/j.ejmech.2016.09.041",
            "pmid": "27744252",
            "xmlid": "CIT0032"
        },
        {
            "bibentry": "Shimizu, S, Kanetaka, H, Hirose, D, et al. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. Dement Geriatr Cogn Disord Extra 2015; 5: 135–46.",
            "process_entry": "True",
            "xmlid": "CIT0033"
        },
        {
            "bibentry": "Karlsson, D, Fallarero, A, Brunhofer, G, et al. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Eur J Pharm Sci 2012; 47: 190–205. PMID: 22683890",
            "process_entry": "True",
            "doi": "10.1016/j.ejps.2012.05.014",
            "pmid": "22683890",
            "xmlid": "CIT0034"
        },
        {
            "bibentry": "Matos, MJ, Viña, D, Vazquez-Rodriguez, S, et al. Focusing on new monoamine oxidase inhibitors: differently substituted coumarins as an interesting scaffold. Curr Top Med Chem 2012; 12: 2210–39. PMID: 23231397",
            "process_entry": "True",
            "doi": "10.2174/156802612805220002",
            "pmid": "23231397",
            "xmlid": "CIT0035"
        },
        {
            "bibentry": "Kim, D, Baik, SH, Kang, S, et al. Close correlation of monoamine oxidase activity with progress of alzheimer's disease in mice, observed by in vivo two-photon imaging. ACS Cent Sci 2016; 2: 967–75. PMID: 28058286",
            "process_entry": "True",
            "doi": "10.1021/acscentsci.6b00309",
            "pmid": "28058286",
            "pmcid": "PMC5200925",
            "xmlid": "CIT0036"
        },
        {
            "bibentry": "Lovell, MA, Markesbery, WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 2007; 85: 3036–40. PMID: 17510979",
            "process_entry": "True",
            "doi": "10.1002/jnr.21346",
            "pmid": "17510979",
            "xmlid": "CIT0037"
        }
    ],
    "localid": "MED-30746966",
    "doi": "10.1080/14756366.2019.1574297",
    "pmid": "10.1080/14756366.2019.1574297",
    "pmcid": "30746966",
    "curator": "BEE EuropeanPubMedCentralProcessor",
    "source_provider": "Europe PubMed Central",
    "source": "https://www.ebi.ac.uk/europepmc/webservices/rest/30746966/fullTextXML",
    "reference_pointers": [
        [
            {
                "n_rp": 0,
                "xref_id": "CIT0001",
                "rp_string": "1",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),315,130)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 1,
                "xref_id": "CIT0002",
                "rp_string": "2",
                "rp_xpath": "/article/body/sec[1]/p[1]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[1]),678,185)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 2,
                "xref_id": "CIT0003",
                "rp_string": "3",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1,113)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 3,
                "xref_id": "CIT0004",
                "rp_string": "4",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),497,165)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 4,
                "xref_id": "CIT0005",
                "rp_string": "5",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),798,161)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 5,
                "xref_id": "CIT0006",
                "rp_string": "6",
                "rp_xpath": "/article/body/sec[1]/p[2]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[2]),1089,131)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 6,
                "xref_id": "CIT0007",
                "rp_string": "7",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 7,
                "xref_id": "CIT0008",
                "rp_string": "8",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 8,
                "xref_id": "CIT0009",
                "rp_string": "9",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 9,
                "xref_id": "CIT0010",
                "rp_string": "10",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[4]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 10,
                "xref_id": "CIT0011",
                "rp_string": "11",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[5]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 11,
                "xref_id": "CIT0012",
                "rp_string": "12",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[6]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 12,
                "xref_id": "CIT0013",
                "rp_string": "13",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[7]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 13,
                "xref_id": "CIT0014",
                "rp_string": "14",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[8]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            },
            {
                "n_rp": 14,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[9]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1,322)",
                "containers_title": [
                    "Introduction"
                ],
                "pl_string": "3-Arylcoumarin refers to a class of compounds having a coumarin skeleton and having an aryl structure at the 3-position, which is rich in biological activity such as antioxidant7, anti-inflammatory8, antitumour9, antiviral10, antifungal11, antidiabetic12, MAO inhibitory activity13,14, ChE inhibitory activity15 and so on. The aetiology of Alzheimer's disease is complex, and for this multi-faceted disease, the efficacy of multi-targeted drugs is better than that of single-targeted drugs. Coumarin compounds, as dual inhibitors, are promising compounds that control AD16–20. Patil et al.21 reviewed the synthesis and designed aspects of coumarin derivatives as MAO inhibitors for AD, in which most 3-arylcoumarin compounds selectively inhibit MAO-B and give some guidance in modifying the structure. Wang et al.15 designed, synthesised, and evaluated a series of 6-substituted 3-arylcoumarin derivatives as dual AChE/MAO-B dual inhibitors for the treatment of AD, which provided meaningful information for further development of multifunctional drugs for AD treatment. Previous studies15,21–24 have designed coumarin derivatives as potential inhibitors of MAO and ChE, and have achieved good results. These results encourage us to further explore the potential of coumarins as candidates for the treatment of AD.",
                "pl_xpath": "/article/body/sec[1]/p[3]"
            }
        ],
        [
            {
                "n_rp": 15,
                "xref_id": "CIT0016",
                "rp_string": "16–20",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[10]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),492,85)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 16,
                "xref_id": "CIT0021",
                "rp_string": "21",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[11]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),578,224)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 17,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[12]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),803,268)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 18,
                "xref_id": "CIT0015",
                "rp_string": "15",
                "rp_xpath": "/article/body/sec[1]/p[3]/xref[13]",
                "context_xpath": "substring(string(/article/body/sec[1]/p[3]),1072,131)",
                "containers_title": [
                    "Introduction"
                ]
            }
        ],
        [
            {
                "n_rp": 19,
                "xref_id": "CIT0025",
                "rp_string": "25",
                "rp_xpath": "/article/body/sec[2]/sec[2]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[2]/p),1,138)",
                "containers_title": [
                    "Experimental",
                    "In vitro cholinesterase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 20,
                "xref_id": "CIT0026",
                "rp_string": "26",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p),1,132)",
                "containers_title": [
                    "Experimental",
                    "In vitro monoamine oxidase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 21,
                "xref_id": "CIT0026",
                "rp_string": "26–28",
                "rp_xpath": "/article/body/sec[2]/sec[3]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[3]/p),134,111)",
                "containers_title": [
                    "Experimental",
                    "In vitro monoamine oxidase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 22,
                "xref_id": "CIT0029",
                "rp_string": "29",
                "rp_xpath": "/article/body/sec[2]/sec[4]/p/xref",
                "context_xpath": "substring(string(/article/body/sec[2]/sec[4]/p),1,179)",
                "containers_title": [
                    "Experimental",
                    "In vitro antioxidant activity"
                ]
            }
        ],
        [
            {
                "n_rp": 23,
                "xref_id": "CIT0030",
                "rp_string": "30",
                "rp_xpath": "/article/body/sec[3]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[1]/p),1,90)",
                "containers_title": [
                    "Results and discussion",
                    "Chemistry"
                ]
            }
        ],
        [
            {
                "n_rp": 24,
                "xref_id": "CIT0031",
                "rp_string": "31–33",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[1]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[1]/p),109,137)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "In vitro cholinesterase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 25,
                "xref_id": "CIT0034",
                "rp_string": "34",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[1]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[1]/p),247,132)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "In vitro cholinesterase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 26,
                "xref_id": "CIT0025",
                "rp_string": "25",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[1]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[1]/p),380,155)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "In vitro cholinesterase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 27,
                "xref_id": "CIT0035",
                "rp_string": "35",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[2]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[2]/p),155,115)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "In vitro monoamine oxidase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 28,
                "xref_id": "CIT0036",
                "rp_string": "36",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[2]/p/xref[2]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[2]/p),155,115)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "In vitro monoamine oxidase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 29,
                "xref_id": "CIT0026",
                "rp_string": "26",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[2]/p/xref[3]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[2]/p),271,114)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "In vitro monoamine oxidase inhibitory activity"
                ]
            }
        ],
        [
            {
                "n_rp": 30,
                "xref_id": "CIT0037",
                "rp_string": "37",
                "rp_xpath": "/article/body/sec[3]/sec[2]/sec[3]/p/xref[1]",
                "context_xpath": "substring(string(/article/body/sec[3]/sec[2]/sec[3]/p),1,207)",
                "containers_title": [
                    "Results and discussion",
                    "Biological evaluation",
                    "In vitro antioxidant activity"
                ]
            }
        ]
    ]
}